Fibbers may have an advantage against Covid-19

I've been seeing a lot of research about the possibility that anti-platelet and anti-coagulants are beneficial for those with Covid 19. I'll post others later.

Please note this is isoquercetin that has a higher bioavailability rate than quercetin dihydrate.


BACKGROUND. Protein disulfide isomerase (PDI) is a thiol isomerase secreted by vascular cells that is required for thrombus formation. Quercetin flavonoids inhibit PDI activity and block platelet accumulation and fibrin generation at the site of a vascular injury in mouse models, but the clinical effect of targeting extracellular PDI in humans has not been studied.

METHODS. We conducted a multicenter phase II trial of sequential dosing cohorts to evaluate the efficacy of targeting PDI with isoquercetin to reduce hypercoagulability in cancer patients at high risk for thrombosis. Patients received isoquercetin at 500 mg (cohort A, n = 28) or 1000 mg (cohort B, n = 29) daily for 56 days, with laboratory assays performed at baseline and the end of the study, along with bilateral lower extremity compression ultrasound. The primary efficacy endpoint was a reduction in D-dimer, and the primary clinical endpoint included pulmonary embolism or proximal deep vein thrombosis.

RESULTS. The administration of 1000 mg isoquercetin decreased D-dimer plasma concentrations by a median of –21.9% (P = 0.0002). There were no primary VTE events or major hemorrhages observed in either cohort. Isoquercetin increased PDI inhibitory activity in plasma (37.0% in cohort A, n = 25, P < 0.001; 73.3% in cohort B, n = 22, P < 0.001, respectively). Corroborating the antithrombotic efficacy, we also observed a significant decrease in platelet-dependent thrombin generation (cohort A median decrease –31.1%, P = 0.007; cohort B median decrease –57.2%, P = 0.004) and circulating soluble P selectin at the 1000 mg isoquercetin dose (median decrease –57.9%, P < 0.0001).

CONCLUSIONS. Isoquercetin targets extracellular PDI and improves markers of coagulation in advanced cancer patients.

[insight.jci.org]

More on this - includes video.



[news.cgtn.com]

I don't have any published information I can point to but I have heard reports that COVID-19 patients are experiencing high rates of hypercoagulation problems. Clots causing kidney failure, liver failure, heart attacks, and strokes have been reported in higher than expected numbers with hospitalized patients. I'd say if you're on an anticoagulant (or should be), now isn't the time to experiment with backing off.

Carey - agreed 1000%

It's possible it may not be a good time to back off D either. But I am upping my C and have added Luteolin and Rutin to my quercetin-zinc-copper regimen as well as strict PPE (goggles, glasses, gloves) for grocery shopping etc.

[clinicaltrials.gov]